Pharmaceuticals
Docquity delivers 10% market share growth for Philippine-based pharmaceutical client in just one year
* Docquity's leading network of HCPs and proprietary Awareness to Advocacy (A2A) solution complemented the Client's Sales and Marketing team to increase conversions in a highly competitive pain product market * Client was able to grow prescriptions and revenue, with over 80% cost savings comp...
Boehringer Ingelheim Malaysia Honored As Top Employer For The Fifth Consecutive Year
* Boehringer Ingelheim is one of 15 global Top Employers worldwide * Achieved Global Recognition and Top Employer Certification in 29 countries From Top Employers Institute® * Outstanding employer benefits with emphasis on wellbeing, attractive work environment, and rewards and recognition...
Boehringer Ingelheim Vietnam Honored As Top Employer For The Fourth Consecutive Year
HO CHI MINH CITY, Vietnam, Jan. 18, 2023 /PRNewswire/ -- Boehringer Ingelheim Vietnam has been honored for the fourth year in succession for its outstanding employee benefits with emphasis on wellbeing, attractive work environment, and rewards and recognition. Globally, Boehringer Ingelheim has ...
Telix Reports Fourth Quarter 2022 Financial Results
MELBOURNE, Australia, Jan. 18, 2023 /PRNewswire/ -- 18 January 2023. Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today issues its Appendix 4C quarterly cash flow statement and accompanying Activities Report for the quarter ended31 December 2022 (Q4 2022). All figures are in AUD$ ...
Transcenta to Present "Trial in Progress" at ASCO-GI 2023 for TST001 (Osemitamab) Combination with Nivolumab, with or without Chemotherapy in Advanced G/GEJ Cancer
SUZHOU, China, Jan. 18, 2023 /PRNewswire/ -- Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics,announces that it will present t...
Everest Medicines Announces Top-line Data from Phase I Study of EVER206 on Healthy Subjects in China
Study findings suggest that EVER206 is well-tolerated with no new safety signals, supporting next-phase clinical development inChina SHANGHAI, Jan. 18, 2023 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest"), a biopharmaceutical company focused on the development, manufacturing and comm...
Abbisko Therapeutics Obtains Approval from The China NMPA to Conduct a Phase II Clinical Study of Pimicotinib (ABSK021) in cGVHD
SHANGHAI, Jan. 18, 2023 /PRNewswire/ -- Abbisko Therapeutics Co., Ltd. ("Abbisko Therapeutics" hereafter) today announced that its CSF-1R inhibitor, pimicotinib (ABSK021), has been approved by the National Medical Products Administration ("NMPA") of the People's Republic ofChina for a phase II c...
Henlius' Novel Anti-PD-1 mAb HANSIZHUANG (Serplulimab) Approved for the Treatment of ES-SCLC
* World's first anti-PD-1 mAb for the first-line treatment of SCLC * Making a new record with the median OS of 15.8 months in an international, multi-center, phase 3 clinical trial * Granted orphan drug designations by the FDA and the EC, paving the way for international commercialization SH...
Ascletis Announces Entering into a Supply Agreement of Ritonavir Tablets with Simcere
HANGZHOU and SHAOXING, China, Jan. 17, 2023 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") today announces that its wholly owned subsidiary Ascletis Pharmaceuticals Co., Ltd. has entered into a supply agreement of ritonavir tablets with Hainan Simcere Pharmaceutical Co., Ltd., a su...
AffaMed Therapeutics to commercialize Galcanezumab for Migraine Prevention in Mainland China
Affamed to obtain sole commercialization rights upon regulatory approval in Mainland China to Galcanezumab, a monoclonal antibody that selectively binds to calcitonin gene-related peptide (CGRP). Target to address unmet medical needs for millions of Chinese migraine patients. SHANGHAI, Jan. 17, ...
JUNIPER BIOLOGICS PARTNERS WITH CARIS LIFE SCIENCES® FOR MOLECULAR PROFILING DISTRIBUTION IN SOUTH EAST ASIA
SINGAPORE, Jan. 12, 2023 /PRNewswire/ -- Singapore-headquartered Juniper
Biologics Pte Ltd
DEBIOPHARM APPLIES EXTENDED-RELEASE FORMULATION EXPERTISE TO REDUCE TREATMENT FREQUENCY BURDEN FOR ACROMEGALY & GEP-NET PATIENTS
- Acromegaly and gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are rare diseases that require life-long chronic treatment. Monthly somatostatin analog (SSA) injections are the standard of care as first-line medical treatment. - Debiopharm is developing Debio 4126, a novel 3-month ext...
CGTN: TCM continues to play significant role in treating COVID-19
BEIJING, Jan. 11, 2023 /PRNewswire/ -- Traditional Chinese Medicine (TCM) has been playing an important role inChina's fight against COVID-19. As China is shifting the focus of its COVID-19 response from preventing infections to protecting people's health and preventing severe cases, the unique...
Bio4t2 announces first patient infused with CAR-T targeting solid tumors
SAN DIEGO, Jan. 11, 2023 /PRNewswire/ -- Bio4t2 dosed the first patient with T cells bearing a chimeric antigen receptor (CAR) that targets overexpression of BT-001 antigen present on various types of solid tumors. The CAR-T (B4t2-001) was developed from Bio4t2's PrismCore™ platform. "This first...
MedAlliance SELUTION SLR is the first DEB to receive coronary de novo IDE approval, its fourth FDA IDE DEB Approval
GENEVA, Jan. 11, 2023 /PRNewswire/ -- SELUTION SLR™, MedAlliance's novel
sirolimus-eluting balloon, has received conditional FDA Investigational Device
Exemption (IDE) approval to initiate its pivotal clinical trial for the
treatment of coronaryde novo lesions.
Innovent Announces First Participant Dosed in a Phase 3 Clinical Study (DREAMS-2) of Mazdutide (IBI362) in Chinese Patients with Type 2 Diabetes
ROCKVILLE, Md. and SUZHOU, China, Jan. 11, 2023 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, metabolic, autoimmune, ophthalmology and ...
Prenetics Owned ACT Genomics Receives FDA Clearance for ACTOnco, the First Asia-Based Company to Receive Clearance for a Comprehensive Genomic Profiling Test for All Solid Tumors
* Prenetics has completed the majority stake acquisition of ACT Genomics to spearhead its entry into to the US$80+ billion global precision oncology market * FDA market authorization advances personalized cancer care in Asia * Clearance sets the stage for continued R&D investment into early d...
Ajinomoto and Exelixis Enter Into a License Agreement to Discover and Develop Novel Antibody-Drug Conjugates for the Treatment of Cancer
TOKYO, Jan. 10, 2023 /PRNewswire/ -- Ajinomoto Co., Inc. ("Ajinomoto Co.") today announced a license agreement with Exelixis, Inc. ("Exelixis") to incorporate AJICAP®, Ajinomoto Co.'s proprietary site-specific bioconjugation and linker technologies, in the development of certain of Exelixis' ant...
Renexxion Announces Opening of Investigational New Drug (IND) Application for Naronapride for the Treatment of Gastrointestinal Dysmotility in Cystic Fibrosis Patients
ROSCREA, Ireland, Jan. 10, 2023 /PRNewswire/ – Renexxion Ireland Limited (Renexxion), a private biopharmaceutical company committed to delivering innovative drugs to patients with high unmet need in gastrointestinal ("GI") disorders, is pleased to announce opening of the Investigational New Drug ...
Treadwell Therapeutics Announces Fast Track Designation Granted by the FDA to CFI-402257 for the Treatment of ER+/HER2- Breast Cancer
NEW YORK, Jan. 10, 2023 /PRNewswire/ -- Treadwell Therapeutics, a clinical-stage biotechnology company, announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to CFI-402257, a best in class inhibitor of Threonine Tyrosine Kinase (TTK, also known as Mps...
Week's Top Stories
Most Reposted
Multiple achievements made in China-Hungary BRI conference
[Picked up by 319 media titles]
2024-05-03 06:59Dow showcases circular and innovative materials science solutions and industry collaborations at Chinaplas 2024
[Picked up by 295 media titles]
2024-04-30 10:11Xinhua president, Hungarian economy minister vow to bolster media cooperation
[Picked up by 289 media titles]
2024-05-03 06:25TAILG Makes Grand Appearance at 2024 Asiabike Jakarta, Aiming to Set the Benchmark in Indonesia
[Picked up by 262 media titles]
2024-05-02 01:21Chinese new energy industry contributes to global green, low-carbon transition
[Picked up by 253 media titles]
2024-04-30 15:13